"阿斯利康一直在讲的，不只是在中国，为全球，中间有非常重要的一个部分，就是在中国，携中国，为全球。" 本次论坛荟聚跨国企业及本土创新力量，阿斯利康全球高级副总裁、全球研发中国负责人何静，阿斯利康国际业务拓展合作与战略投资副总裁陈冰，诚益生 物中国临床研发负责人朱波，和铂医药产品开发事业部总裁陶晓路，Evinova中国总经理张杰共同出席，围绕中国医药创新的关键驱动力、前沿疗法、产学 研合作等话题深入交流，共同展望中国医药创新生态的可期未来。 作为阿斯利康合作企业的代表，诚益生物在2023年与阿斯利康达成了基于一款口服小分子GLP-1药物的独家许可协议；和铂医药则在进博会前夕落成了全新 创新实验室，毗邻阿斯利康全球研发北京战略中心。 诚益生物与和铂医药只是阿斯利康创新生态圈的合作伙伴代表。自2023年以来，阿斯利康已经和14家中国本土创新药企达成15次授权合作，覆盖抗体偶联药 物、细胞疗法、小分子和抗体等前沿技术领域。并且，阿斯利康自2023年来已支持28家中国创新企业全球化发展。 "我们对自己的定位，不仅仅是一家在中国开展业务的跨国公司，而是要内嵌到整个中国研发生态体系建设当中，成为这个体系重要贡献者之一，同时 ...

Core Insights - Crystal Technology's subsidiary Ailux has entered into a multi-target strategic collaboration and platform licensing agreement with Eli Lilly, valued at up to $345 million [2] - This partnership follows a previous $250 million agreement for AI small molecule drug collaboration, highlighting the ongoing relationship between the two companies [2] - The collaboration aims to accelerate the discovery and development of bispecific antibodies using Ailux's proprietary platform, showcasing the international recognition of its AI capabilities in drug development [2][3] Company Overview - Ailux, established by Crystal Technology in 2021, focuses on the development of large molecule drugs and has rapidly progressed in commercial outcomes over the past two years [3] - The platform integrates quantum physics, AI, and high-throughput wet lab capabilities to design high-potential antibody drugs targeting complex disease mechanisms [3] - Ailux has successfully served multiple top international pharmaceutical companies and validated its platform in several research projects [3] Market Potential - Antibodies are a core drug form that outperforms small molecules in terms of annual growth rate, blockbuster drug ratio, and clinical success rates [2] - The global drug market for antibodies is projected to grow from $288.4 billion in 2025 to $628.5 billion by 2035, indicating a continuous increase in market share [2]

Core Viewpoint - The biopharmaceutical ETF (159859) has seen significant trading activity and net inflows, indicating strong investor interest in the sector, particularly in innovative drug companies [3][4][5]. Group 1: ETF Performance - As of November 4, the biopharmaceutical ETF (159859) has increased by 22.58% over the past six months, ranking first among comparable funds [4]. - The ETF has achieved a recent high in total shares, reaching 7.674 billion shares [4]. - In the last week, the ETF experienced an average daily trading volume of 139 million yuan, also ranking first among comparable funds [4]. Group 2: Fund Inflows - The biopharmaceutical ETF (159859) has seen a net inflow of 122 million yuan over the past four days [4]. - The innovative drug ETF Tianhong (517380) has also experienced net inflows totaling 61.32 million yuan in the same period [5]. Group 3: Market Trends - The recent negotiations for the national basic medical insurance drug catalog have concluded successfully, with 120 companies participating, indicating a stable pricing mechanism for drugs [6]. - The average price reduction for drugs in recent years has stabilized, with the expected burden reduction for patients exceeding 50 billion yuan in 2025 [6]. - Analysts from Zhongtai Securities suggest that despite a weak performance in the pharmaceutical sector in October, the fundamentals remain strong, and innovative drugs are expected to rebound [6].

Group 1: Liquidity and Fund Performance - The Hong Kong Stock Connect Innovative Drug ETF managed by Harvest saw an intra-day turnover of 7.76%, with a transaction volume of 76.0143 million yuan [2] - Over the past year, the average daily transaction volume of the ETF reached 116 million yuan [2] - In the past week, the ETF's scale increased by 39.7287 million yuan, ranking first among comparable funds [2] - The latest share count for the ETF reached 1.046 billion shares [2] - The ETF experienced a net inflow of 14.1619 million yuan, with a total of 46.8442 million yuan net inflow over three of the last five trading days [2] Group 2: Valuation and Index Composition - The latest price-to-earnings ratio (PE-TTM) for the index tracked by the ETF is 31.84, which is in the 19.17th percentile over the past three years, indicating a valuation lower than 80.83% of the time in the last three years [2] - As of October 31, 2025, the top ten weighted stocks in the index include WuXi Biologics, Innovent Biologics, BeiGene, and others, collectively accounting for 71.11% of the index [2] Group 3: Policy and Market Outlook - The first version of the commercial insurance innovative drug directory is set to be released, with negotiations for the 2025 National Basic Medical Insurance Drug Directory concluding successfully [3] - A total of 120 domestic and foreign enterprises participated in the negotiations, with 127 drugs outside the directory involved in the bidding process [3] - The innovative drug industry is expected to remain in a golden development period, benefiting from advancements in clinical development and a rich pipeline of innovative drugs [3] - AI drug development and gene therapy technologies are anticipated to bring new breakthroughs in the coming years [3]

Group 1 - The "Tianhe Supercomputing Power Ecological Conference" was held in Linyi, Shandong, focusing on the integration of research, computing, application, and production, with the Linyi intelligent computing node connected to the Tianhe computing network as a key highlight [1] - The conference featured three high-end forums on high-performance computing, AI innovation applications, and industrial digital intelligence, and launched the Tianhe AI Joint Laboratory, soliciting intelligent development solutions across various sectors [1] - The Tianhe Digital Numerical Smart City platform and Enterprise Innovation Cloud were introduced, aimed at providing diverse services and mature solutions for comprehensive urban governance and the development of domestic software [1] Group 2 - The Tianhe Supercomputing Center's resources primarily focus on anti-tumor projects, significantly reducing the project delivery cycle from three years to one year through the use of supercomputing power [2] - The Tianhe Supercomputing Center's Huaihai Branch has served over 1,000 enterprises in the surrounding area since its establishment in 2020, enhancing the local pharmaceutical industry's capabilities [2] - Future plans include leveraging the Tianhe computing network to support various industries and contribute to the national computing network strategy and the construction of a digital China [2]

Group 1 - A new stock subscription is available for Beikuan Testing with a subscription code of 920160 and an issue price of 6.7 yuan per share, with a subscription limit of 1.2744 million shares [4] - The State Council meeting on October 31 focused on deepening reforms in key areas and expanding institutional openness, aiming to enhance the level of market openness and gradually expand rules and standards [4] - The Ministry of Finance and the State Taxation Administration announced tax policies regarding gold transactions, exempting value-added tax for certain transactions until the end of 2027 [4] Group 2 - The China Securities Regulatory Commission released a draft guideline for the performance comparison benchmarks of publicly raised securities investment funds, aiming to standardize benchmarks and enhance the investment discipline of public funds [5] - A significant breakthrough in nuclear energy was reported, with China achieving thorium-uranium fuel conversion based on molten salt reactors, marking a key opportunity for the country's nuclear energy sector [5] - As of October 31, 2025, a report indicated that 5,446 listed companies in China showed continuous improvement in performance, with a notable emphasis on innovation and high-quality development [6] Group 3 - Anshi China has established sufficient finished and in-process inventory to meet customer demand until the end of the year and beyond, ensuring supply chain reliability [8] - Vanke A is set to receive a loan limit of up to 22 billion yuan from Shenzhen Metro Group [8] - Long-term partnerships and strategic collaborations are being formed, such as the agreement between Beida Pharmaceutical and Shengsi Bio, and the strategic cooperation framework between Tianqi Technology and Foxconn Automotive [8]

Group 1 - New stock subscription: Beikang Testing with subscription code 920160, issue price 6.7 CNY/share, subscription limit of 1.2744 million shares [5] - The State Council meeting on October 31 focused on deepening reforms in key areas and expanding institutional openness, aiming to enhance the openness of the commodity market [5] - The Ministry of Finance and the State Taxation Administration announced tax policies regarding gold, exempting VAT for transactions involving standard gold until the end of 2027 [5] Group 2 - The China Securities Regulatory Commission released a draft guideline for the performance comparison benchmarks of publicly offered securities investment funds, aiming to standardize the industry and enhance long-term stable returns for investors [6] - A significant breakthrough in nuclear energy was reported, with China achieving thorium-uranium fuel conversion based on molten salt reactors, marking a shift from uranium dependency [6] - As of October 31, 2025, 5,446 listed companies in China reported improved performance, with a notable emphasis on innovation and high-quality development [8] Group 3 - Anshi China has established sufficient finished and in-process inventory to meet customer demand until the end of the year and beyond, ensuring supply chain reliability [10] - Vanke A is set to receive a loan limit of up to 22 billion CNY from Shenzhen Metro Group [10] - Long-term growth in the new energy vehicle sector is highlighted, with Chang'an Automobile reporting a 36.14% year-on-year increase in sales for October 2025 [10][11]

Core Insights - The company has optimized its project structure, with over 1,100 early-stage projects (from preclinical to Phase II) and 53 projects in Phase III and commercialization as of the first half of 2025, indicating a trend towards accelerated project conversion [2] - The company successfully assisted in the approval of two innovative drugs in 2025, reflecting a positive shift towards later-stage project commercialization [2] - The domestic market shows favorable conditions due to supportive policies, including accelerated new drug reviews and expanded insurance coverage, while the overseas market is expected to improve financing conditions for biotech companies due to a shift to a rate-cutting cycle in the U.S. [2] Company Performance - The total expenses for sales, management, R&D, and financial costs for the first three quarters of 2025 amounted to 283 million yuan, a year-on-year decrease of 9.88%, with expense ratios maintained at around 20% [2] - The company plans to increase investment in new technology platforms such as AI drug development and continuous flow chemistry, which may lead to a rise in R&D expenses in the future [2] Market Outlook - The company maintains an optimistic outlook on the growth of global CDMO demand over the next two years, supported by both domestic and international market signals [2]

Core Insights - Haoyuan Pharmaceutical reported a revenue of 2.06 billion yuan for the first three quarters of 2025, marking a year-on-year increase of 27.2% and a net profit of 240 million yuan, up 65.1% [1] - The company’s gross margin reached 49.7%, an increase of 2.2 percentage points compared to the previous year, indicating strong operational efficiency [1] - The company is actively implementing a development strategy focused on "industrialization, globalization, and branding," which has led to sustained high growth in operational performance [1] Front-End Business - The life science reagent business has shown robust growth, generating 1.45 billion yuan in revenue, a year-on-year increase of over 31%, accounting for more than 70% of the company's main business revenue [1] - The company has accumulated over 152,000 types of life science reagents, including over 96,000 molecular building blocks, ensuring a diverse product offering that supports customer needs and contributes to stable profit [1] Back-End Business - The back-end business, focusing on high-difficulty and high-barrier R&D technology platforms, achieved a revenue of 600 million yuan, reflecting a year-on-year growth of 16.9% [2] - The order backlog for small molecule business reached 630 million yuan, a 50% increase year-on-year, indicating a positive growth trend over four consecutive quarters [2] ADC Development - Haoyuan Pharmaceutical has successfully undertaken over 90 ADC projects, enhancing clients' drug development processes [3] - The company has formed strategic partnerships with Maiwei Bio and Yingshi Intelligent to advance ADC drug innovation, establishing a new model that integrates AI, biotech, and CDMO services [3] AI and Drug Development - The company is focused on developing an AI-driven drug discovery platform, aiming to create a one-stop drug screening service that can quickly identify potential drug candidates [4] - The platform includes hundreds of compound libraries and utilizes AI technology to explore a broader chemical space, offering various screening techniques and optimization services for new drug development [4]

Core Insights - The company reported significant growth in its financial performance for the first three quarters of 2025, with revenue reaching 683 million yuan, a year-on-year increase of 82.06%, and a net profit of 71.35 million yuan, marking a turnaround from losses [1] - The operational cash flow reached a historical high of 271 million yuan, reflecting a year-on-year growth of 207.37%, driven by the successful market penetration of its core product, liraglutide injection [1] Financial Performance - Revenue for the first three quarters was 683 million yuan, up 82.06% year-on-year [1] - Net profit attributable to shareholders was 71.35 million yuan, indicating a return to profitability [1] - Operating cash flow was 271 million yuan, representing a 207.37% increase year-on-year, the highest in the same period historically [1] Technological Innovation - The company launched a "Peptide AI Process Optimization Assistant" in collaboration with Huawei Cloud, utilizing over 100,000 historical process data points and global chemical databases to enhance drug development efficiency [2] - The AI assistant has reportedly reduced research and development cycles by 45% and lowered trial and error costs by over 20% [2] - The company is also advancing in new peptide sustained-release technologies, improving drug delivery convenience and optimizing drug action duration [2] CRDMO Business Expansion - The company has been active in the CRDMO (Contract Research, Development, and Manufacturing Organization) sector, forming strategic partnerships to enhance its business ecosystem [3] - Collaborations with Carbon Cloud Peptide focus on innovative peptide drug development, covering the entire process from preclinical research to commercialization [3] - The partnership with Borui Pharmaceutical aims to provide international standard raw material supply for oral peptide products, supporting global industrialization of innovative drugs [3] Capital Increase and Capacity Expansion - The company announced a plan to raise up to 968 million yuan through a private placement to enhance its core peptide drug business [4] - Of the raised funds, 495 million yuan will be allocated to expanding peptide drug production lines and green intelligent upgrades to ensure continuous supply of raw materials [4] - The plan also includes investing 40 million yuan in expanding peptide fragment production, aiming for vertical integration in the pharmaceutical supply chain [4]